Avantor (AVTR) reported earnings 30 days ago. What's next for the stock?
AVTR's Revival Program is lifting VWR growth and BMP orders, but margin pressure and soft earnings keep the recovery selective despite a higher 2026 outlook.
Here is how Avantor, Inc. (AVTR) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.
Here is how Avantor, Inc. (AVTR) and Johnson & Johnson (JNJ) have performed compared to their sector so far this year.
Avantor, Inc. (AVTR) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, AVTR's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
AVTR tops Q2 earnings and revenue estimates as VWR returned to organic growth early, prompting higher 2026 revenues and earnings guidance.
Avantor NYSE: AVTR reported second-quarter 2026 results that exceeded its expectations on several measures, supported by a return to organic growth in its VWR Distribution & Services segment, strong free cash flow and progress under its Revival operational improvement program.
The headline numbers for Avantor (AVTR) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Avantor, Inc. (AVTR) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.24 per share a year ago.
Avantor (AVTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors interested in stocks from the Medical Services sector have probably already heard of Avantor, Inc. (AVTR) and Icon PLC (ICLR). But which of these two stocks is more attractive to value investors?
Avantor (AVTR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.